Navigation Links
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
Date:10/30/2013

nexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCindy McGee, Vice President,

David Schull, PresidentInvestor Relations & Alliance Management

david.schull@russopartnersllc.comcmcgee@arenapharm.com

858.717.2310858.453.7200, ext. 1479 www.arenapharm.com   

 


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Persistence Market ... "Global Market Study on Ophthalmic Devices: Asia ... global ophthalmic devices market was valued at USD 29,171.5 million in ... of 6.5% from 2014 to 2020, to reach an ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... , Sept. 22, 2014  AVT, Inc. (OTC ... retailing systems and custom vending machines, announced today that ... Unit. This new, smaller sized unit is designed for ... practices. According to industry statistics, there are ... Opticwash is the world,s first automated kiosk ...
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) ... investigator at Emory University, presented long-term follow up data ... stem cells in the treatment of amyotrophic lateral sclerosis ... which occurred at the Annual Symposium on ALS of ... , on Friday, and was not open to the ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4
... 29, 2011 CryoLife, Inc. (NYSE: CRY ... processing company, and Cardiogenesis Corporation (OTCQB: CGCP), a leading ... patients with refractory angina resulting from diffuse coronary artery ... both companies have approved a definitive agreement under which ...
... March 29, 2011 Tris Pharma, Inc., a specialty ... the MyKidz® Iron product line.  Since the ... loyal following of pediatricians, pediatric nurses and mothers.  When ... in a different direction, availability of MyKidz Iron™ became ...
Cached Medicine Technology:CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 2CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 3CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 4CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 5CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 6CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 7CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 8CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 9CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 10CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 11CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 12CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 13CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 14CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 15CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 16CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 17CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 18Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 2Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 3
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... a new report detailing the continued use of ... federal regulators that specifically discouraged these procedures. According ... that the potential cancer risks associated with power ...
(Date:9/22/2014)... Gray HealthDay Reporter MONDAY, ... woman wonders: What can I do to help ensure a ... as prescribed may play a role in reducing the risk ... The researchers found that mothers of children with autism were ... during pregnancy than those whose children seem to be developing ...
(Date:9/22/2014)... In a continued effort to support ... is launching an awareness campaign inspired by the ice ... aims to raise awareness and funds for the cause. ... in the air and trying to catch it while ... a nominee does not complete the challenge within 24 ...
(Date:9/22/2014)... Ind. Researchers have developed a chip capable ... use the new system to test the effectiveness ... new system, called a tumor-microenvironment-on-chip (T-MOC) device, will ... tumors and the barriers that prevent the targeted ... Purdue University associate professor of mechanical engineering., Researchers ...
(Date:9/22/2014)... 22, 2014 The New York Group ... Surgery at the Icahn School of Medicine at Mount ... Group for Plastic Surgery gives residents of New York ... team of world-renowned plastic surgeons performing innovative reconstructive and ... MD, who led NYGPS, was named the Director of ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... 24 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, has announced the appointment of Dr. Marcel ... Affairs. Prior to joining Sopherion, Dr. Rozencweig was ... and a member of the Sopherion Protocol Development ...
... ON, Feb. 24 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: ... research and development of drug products delivered to and ... delivery technologies, today announced that Nuvo,s INSIGHT(TM) platform, developed ... fqubed, Inc., has been selected as one of four ...
... of Nearly 106 Million PrescriptionsStrong 2009 EPS Guidance ReaffirmedFourth-Quarter ... percent to $0.54 from $0.38 in 2007 , - ... from the 2003 spin-off, increased 37.2 percent to $0.59 ... volume of 26.7 million increased 9.4 percent from 2007 ...
... a medical imaging and diagnostic Company launches new Physician Billing Services ... billing services as part of its commitment to synergistically diversify the ... ... 2009 -- Bederra Corporation (Pink Sheets: BEDA), a medical ...
... 24 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and year ended December 31, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO )For ... loss of $33.4 million, or $0.91 per share, compared ... per share, in the fourth quarter of 2007. Weighted ...
... Healthcare Workers from Hazardous Drug ExposureCOLUMBUS, Ohio, Feb. 24 ... the safe handling of hazardous drugs in the healthcare ... Safe Handling Awareness Month with Monday, April 20, 2009 ... The proclamation of National Safe Handling Awareness Month ...
Cached Medicine News:Health News:Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 2Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 4Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 5Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 6Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 7Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 8Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 9Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 10Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 11Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 12Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 13Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 14Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 15Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 16Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 17Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 18Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 19Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 20Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 21Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 22Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 23Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 24Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 25Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 26Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 27Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 28Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 29Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 30Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 2Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 3Health News:Rigel Announces Fourth Quarter and Year End 2008 Financial Results 2
... The ACE Titanium Small Fragment System ... the surgeon with superior implants and user-friendly ... and cannulated screws, and fracture instrumentation is ... necessary armamentarium to utilize current and classic ...
... The CARDIA PDA Closure Device has ... the Patent Ductus Arteriosus. Introduced through standard ... safe and reliable method for the percutaneous ... size from 2mm-10mm within the ductus.,An integral ...
Swanson Finger Pins are stainless steel and available in one length and three diameters....
Round Bevel-Point Hook Pin available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Medicine Products: